IRVINE, Calif., April 25, 2012 /PRNewswire/ -- Aviir Diagnostic Laboratory announced today that it has entered into a contractual agreement with MultiPlan, Inc. for ancillary diagnostics laboratory testing. The agreement includes Aviir’s participation in the MultiPlan, PHCS and PHCS Savility Networks.
Aviir was founded in 2005 by cardiologists and scientists from the Stanford University School of Medicine to focus on discovery, development and commercialization of innovative diagnostic tests. The biotechnology company specializes in developing proprietary diagnostic tests that will assist in identifying patients who are truly at high risk for the development of a cardiac event. Aviir’s proprietary MiRisk and TruRisk assessments objectively identify, by a simple blood draw, individuals who are at a high risk of a cardiac event over the next five years. Aviir’s CLIA laboratory (Irvine, CA) complements these novel tests with a wide range of additional tests for risk assessment and therapeutic monitoring of cardiovascular disease and related metabolic disorders including pharmacogenomics and genetic tests. www.aviir.com
Aviir’s agreement with MultiPlan will give MultiPlan’s participating providers and its clients’ members access to Aviir’s tests. Approximately 900,000 providers participate in MultiPlan’s provider networks and an estimated 57 million consumers have access to one or more of these networks.
“There is currently a significant yet unmet clinical need in the medical community for more effective ways to identify individuals at high risk of a heart attack who are missed by current evaluation methods. Providing an accurate assessment of the patient’s overall heart health is the first step in prevention of cardiovascular disease,” stated Douglas Harrington, M.D., Chief Executive Officer of Aviir. “Our agreement with MultiPlan will help ensure more doctors and therefore patients have access to the tools that can provide the accurate assessment.”
“At Aviir, our ultimate goal is to help physicians identify those patients who are at serious risk of experiencing a heart attack but are completely unaware of their precarious condition. Armed with better information, physicians will be able to customize individualized treatment plans with the goal of improving patient therapeutic compliance, reduce their risk of heart attacks, and decrease the overall cost of care.” Dr. Harrington added.
Learn more about Aviir at www.aviir.com.
Learn more about MultiPlan at www.multiplan.com.
For more information:
Dina Scaglione
(949) 910-9401
dina.scaglione@aviir.com
SOURCE Aviir Diagnostic Laboratory
